Skip to main navigation Skip to search Skip to main content

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

  • , Stephen Begbie
  • , Mark Frydenberg
  • , Louise Nott
  • , Zulfiquer Otty
  • , Francis X. Parnis
  • , David Pook
  • , Shahneen Sandhu
  • , Sanjeev Sewak
  • , Amanda Stevanovic
  • , Martin Stockler
  • , Aneta Suder
  • , Hsiang Tan
  • , Javier Torres
  • , Simon Troon
  • , Craig Underhill
  • , Andrew Weickhardt
  • , Robert R. Zielinski
  • , Tahir Abbas
  • , Ghadeer Anan
  • Chris Booth, Holly Campbell, Joseph Chin, Edmond Chouinard, Bryan Donnelly, Darrel Drachenberg, Amir Faghih, Antonio Finelli, Sebastien Hotte, Krista Noonan, Scott North, Mohammad Rassouli, Neil Reaume, Ricardo Rendon, Fred Saad, Evgeny Sadikov, Eric Vigneault, Pawel Zalewski, John McCaffrey, Ray McDermott, Patrick Morris, Miriam O'Connor, Paul Donnellan, Dearbhaile O'Donnell, Jim Edwards, Peter Fong, Alvin Tan, Simon Chowdhury, Simon Crabb, Omar Khan, Vincent Khoo, Graham Macdonald, Heather Payne, Angus Robinson, Jonathon Shamash, John Staffurth, Carys Thomas, Alastair Thomson, Christopher J. Sweeney

Research output: Contribution to journal › Article › peer-review

204 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry